Evidence map›Paper›PMID 26333068›Full record

ArticlePLoS pathogens2015

Suppression of a Natural Killer Cell Response by Simian Immunodeficiency Virus Peptides.

Jamie L Schafer, Moritz Ries, Natasha Guha, Michelle Connole, Arnaud D Colantonio, Emmanuel J Wiertz, Nancy A Wilson, Amitinder Kaur, David T Evans

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. OMIP-035: Functional analysis of natural killer cell subsets in macaques.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2016
    Article
  10. Animal models to achieve an HIV cure.Current opinion in HIV and AIDS · 2016
    Review
  11. Roles of natural killer cells in antiviral immunity.Current opinion in virology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jamie L SchaferDepartment of Microbiology and Immunobiology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
Moritz RiesDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
Natasha GuhaDepartment of Microbiology and Immunobiology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
Michelle ConnoleDivision of Immunology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
Arnaud D ColantonioDivision of Immunology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
Emmanuel J WiertzDepartment of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Nancy A WilsonDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.
Amitinder KaurDivision of Immunology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
David T EvansDepartment of Microbiology and Immunobiology, Harvard Medical School, New England Primate Research Center, Southborough, Massachusetts, United States of America.
Harvard University · USUniversity of Wisconsin–Madison · USUniversity Medical Center Utrecht · NL

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
New England Primate Research Center Base GrantP51OD011103 · OD · HARVARD MEDICAL SCHOOL · PI FLIER, JEFFREY S · 2012 to 2013
$24.7M
Sustained antibody delivery for durable suppression of immunodeficiency virus replicationR01AI121135 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2015 to 2026
$6.9M
KIR and MHC Class I Immunogenetics in SIV InfectionR37AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI David T Evans · 2019 to 2026
$5.6M
KIR and MHC Class I Immunogenetics in SIV InfectionR01AI095098 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.7M
Lentiviral Resistance to TetherinR01AI098485 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T · 2012 to 2016
$2.2M
The NEPRC SPF Rhesus Macaque Breeding ColonyU42OD010849 · OD · HARVARD MEDICAL SCHOOL · PI SPEALMAN, ROGER D · 2012 to 2014
$2.2M
NIAID NIH HHS AI095098NIAID NIH HHS AI098485NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI095098NIAID NIH HHS R01 AI098485NIAID NIH HHS R01 AI121135NIAID NIH HHS R37 AI095098NIH HHS OD010849NIH HHS OD011103NIH HHS P51 OD011103NIH HHS P51 OD011104NIH HHS U42 OD010849
6 · The paper itself

Abstract

Natural killer (NK) cell responses in primates are regulated in part through interactions between two highly polymorphic molecules, the killer-cell immunoglobulin-like receptors (KIRs) on NK cells and their major histocompatibility complex (MHC) class I ligands on target cells. We previously reported that the binding of a common MHC class I molecule in the rhesus macaque, Mamu-A1*002, to the inhibitory receptor Mamu-KIR3DL05 is stabilized by certain simian immunodeficiency virus (SIV) peptides, but not by others. Here we investigated the functional implications of these interactions by testing SIV peptides bound by Mamu-A1*002 for the ability to modulate Mamu-KIR3DL05+ NK cell responses. Twenty-eight of 75 SIV peptides bound by Mamu-A1*002 suppressed the cytolytic activity of primary Mamu-KIR3DL05+ NK cells, including three immunodominant CD8+ T cell epitopes previously shown to stabilize Mamu-A1*002 tetramer binding to Mamu-KIR3DL05. Substitutions at C-terminal positions changed inhibitory peptides into disinhibitory peptides, and vice versa, without altering binding to Mamu-A1*002. The functional effects of these peptide variants on NK cell responses also corresponded to their effects on Mamu-A1*002 tetramer binding to Mamu-KIR3DL05. In assays with mixtures of inhibitory and disinhibitory peptides, low concentrations of inhibitory peptides dominated to suppress NK cell responses. Consistent with the inhibition of Mamu-KIR3DL05+ NK cells by viral epitopes presented by Mamu-A1*002, SIV replication was significantly higher in Mamu-A1*002+ CD4+ lymphocytes co-cultured with Mamu-KIR3DL05+ NK cells than with Mamu-KIR3DL05- NK cells. These results demonstrate that viral peptides can differentially affect NK cell responses by modulating MHC class I interactions with inhibitory KIRs, and provide a mechanism by which immunodeficiency viruses may evade NK cell responses.

Indexed as

Immune EvasionAllelesAmino Acid SubstitutionAnimalsCD4-Positive T-LymphocytesCell LineCells, CulturedCoculture TechniquesEpitopes, T-LymphocyteHistocompatibility Antigens Class IKiller Cells, NaturalLigandsMacaca mulattaPeptidesReceptors, KIRRecombinant ProteinsEpitopes, T-LymphocyteHistocompatibility Antigens Class ILigandsMamu-A 01 antigenPeptidesReceptors, KIRRecombinant ProteinsViral Proteins

Identifiers

PMID26333068
PMCPMC4557930
OpenAlexW1910621484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.